全文获取类型
收费全文 | 17338篇 |
免费 | 1301篇 |
国内免费 | 597篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 184篇 |
妇产科学 | 151篇 |
基础医学 | 971篇 |
口腔科学 | 743篇 |
临床医学 | 1541篇 |
内科学 | 2751篇 |
皮肤病学 | 406篇 |
神经病学 | 513篇 |
特种医学 | 681篇 |
外科学 | 1579篇 |
综合类 | 1810篇 |
现状与发展 | 1篇 |
预防医学 | 1037篇 |
眼科学 | 156篇 |
药学 | 5068篇 |
4篇 | |
中国医学 | 335篇 |
肿瘤学 | 1239篇 |
出版年
2024年 | 23篇 |
2023年 | 217篇 |
2022年 | 418篇 |
2021年 | 605篇 |
2020年 | 574篇 |
2019年 | 596篇 |
2018年 | 597篇 |
2017年 | 570篇 |
2016年 | 648篇 |
2015年 | 695篇 |
2014年 | 1084篇 |
2013年 | 1770篇 |
2012年 | 1084篇 |
2011年 | 1119篇 |
2010年 | 856篇 |
2009年 | 833篇 |
2008年 | 808篇 |
2007年 | 840篇 |
2006年 | 657篇 |
2005年 | 659篇 |
2004年 | 523篇 |
2003年 | 491篇 |
2002年 | 398篇 |
2001年 | 335篇 |
2000年 | 282篇 |
1999年 | 219篇 |
1998年 | 191篇 |
1997年 | 230篇 |
1996年 | 154篇 |
1995年 | 162篇 |
1994年 | 135篇 |
1993年 | 146篇 |
1992年 | 126篇 |
1991年 | 130篇 |
1990年 | 103篇 |
1989年 | 98篇 |
1988年 | 97篇 |
1987年 | 94篇 |
1986年 | 75篇 |
1985年 | 81篇 |
1984年 | 81篇 |
1983年 | 62篇 |
1982年 | 57篇 |
1981年 | 46篇 |
1980年 | 46篇 |
1979年 | 43篇 |
1978年 | 38篇 |
1977年 | 31篇 |
1976年 | 34篇 |
1973年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
目的评价酒石酸长春瑞滨长循环热敏脂质体(V-LCTL)对荷瘤小鼠的药效和不良反应。方法建立荷Lewis肺癌小鼠皮下肿瘤模型,静脉注射药品,比较V-LCTL与酒石酸长春瑞滨注射液(V-I)、酒石酸长春瑞滨长循环脂质体(V-LCL)的抗肿瘤作用,包括肿瘤生长曲线,抑瘤率,考察给药频率及量效关系。结果各治疗组均有抑瘤作用。相同剂量下V-LCTL的抑瘤效果明显强于V-LCL和V-I。单次给药和多次给药对V-LCTL和V-I的抑瘤率无显著影响。单次给药时不良反应明显。V-LCTL的抑瘤效果呈剂量依赖性(低、中、高剂量组抑瘤率分别为54.6%,72.1%,81.5%)。结论 V-LCTL具有比V-I和V-LCL更好的抑瘤效果,多次给药不良反应小,且V-LCTL的抑瘤效果具有剂量依赖关系。 相似文献
992.
目的 总结肾移植后使用不同免疫抑制方案的效果和不良反应,以提高人/肾的长期存活率.方法 对单中心3102例肾移植受者的临床资料进行回顾性分析,所采用的免疫抑制方案有环孢素A(CsA)+硫唑嘌呤(Aza)+泼尼松(Pred)、低剂量CsA+吗替麦考酚酯(MMF)+Pred、低剂量他克莫司(Tac)+MMF+Pred、低剂量CsA(或Tac)+西罗莫司(SRL)+Pred等方案,分析各方案的效果和不良反应.结果 低剂量CsA+MMF+Pred方案的人/肾1、5、10年存活率均高于CsA+Aza+Pred方案,而高血压、震颤、高尿酸、肝肾毒性、白细胞下降等的发生率显著低于CsA+Aza+Pred方案(P<0.05),腹泻发生率显著高于CsA+Aza+Pred方案(P<0.05).低剂量Tac+MMF+Pred方案的高血糖发生率显著高于低剂量CsA+MMF+Pred方案(P<0.05),多毛症发生率显著低于低剂量CsA+MMF+Pred方案(P<0.05);低剂量CsA(或Tac)+SRL+Pred方案的腹泻、高尿酸血症、肝肾毒性和多毛症等的发生率显著低于低剂量CsA(或Tac)+MMF+Pred方案(P<0.05),但高血脂发生率显著高于后者(P<0.05).以低剂量Tac为基础的方案者高血糖发生率显著应用低剂量CsA者.结论 低剂量CsA(或Tac)+MMF+Pred方案改善了肾移植受者和移植肾的存活,降低了不良反应发生率,尤以低剂量Tac+MMF+Pred方案为优;调整免疫抑制方案或剂量,改善饮食习惯,加强锻炼,优化降血压、降血脂、控制血糖的治疗措施对预防和控制不良反应尤为重要.Abstract: Objective To summarize the incidence and treatment experience of the effectiveness and adverse reactions of the different immunosuppressive protocols and to increase the long-term survival rate in kidney recipients. Methods Single-center retrospective analysis was performed on 3102 cases of kidney transplant recipients in effectiveness and adverse reactions of different immunosuppressive protocols. The immunosuppressive protocols were as follows: CsA + Aza + Pred,low dose CsA + MMF + Pred, low dose Tac + MMF + Pred, low dose CsA + SRL + Pred, and low dose Tac+ SRL+ Pred. Results The 1-, 5-, 10-year survival rate of patients/kidney in low dose CsA + MMF + Pred protocol was higher than that in CsA + Aza + Pred protocol. The incidence of adverse reactions, such as hypertension, hyperuricemia, kidney and liver toxicity, and leukopenia was significantly lower, but the incidence of diarrhea was significantly higher in CsA + MMF + Pred protocol than in CsA + Aza + Pred protocol (all P<0. 01). The incidence of hyperglycemia was significantly higher (P<0. 05), and that of hairy and gingival hyperplsia was significantly lower (P<0. 05) in low dose Tac+ MMF+ Pred than in low dose CsA+ MMF+ Pred protocol. The incidence of hyperlipidemia in low dose CsA (or Tac)+ SRL + Pred was significantly higher than in CsA (or Tac)+ MMF+ Pred protocol (P<0. 05). The incidence of hirsutism in low dose Tac + SRL + Pred was significantly lower than that in CsA + SRL + Pred protocol (P < 0. 05). The incidence of hyperglycemia in low dose Tac + SRL + Pred was significantly higher than that in low dose CsA + SRL + Pred protocol. Conclusion The triple drug protocol with a low dose of CsA (or Tac)+ MMF+ Pred significantly improved the survival of renal transplant recipients and graft, and reduced the incidence of adverse reactions, especially Tae + MMF + Pred protocol. Adjustment of the immunosuppressant dosage and protocol, improvement of eating habits, exercise, reduction of blood pressure, reduction of blood lipid, and control of blood glucose were particularly important in preventing and controlling adverse reactions during kidney transplantation. 相似文献
993.
医用透明质酸钠预防腹部手术后腹腔粘连的临床观察 总被引:9,自引:0,他引:9
目的 观察医用透明质酸钠对预防腹部手术后腹腔粘连的作用。方法 136 0例腹部手术患者 ,关腹前于腹膜及腹腔创面涂抹医用透明质酸钠 (sodiumhyaluronate)凝胶剂 3~ 15ml,随访期间 ,2 3例患者获 2次手术探察的机会 ,观察腹腔粘连程度 ,并与同期未用透明质酸钠凝胶剂的 2 6例 2次手术患者作对比分析。结果观察组 :腹腔粘连Ⅰ级 11例 ,Ⅱ级 9例 ,Ⅲ级 3例 ,Ⅳ级 0例 ;对照组 :Ⅰ级 1例 ,Ⅱ级 5例 ,Ⅲ级 17例 ,Ⅳ级 3例。两组轻度粘连分别为 87%和 2 3% ;两组重度粘连分别为 13%和 77%。两组患者手术后腹腔内粘连情况比较 ,差异有显著意义 (P <0 0 1)。结论透明质酸钠凝胶对腹部手术后预防腹腔粘连具有明显效果。 相似文献
994.
995.
Molecular-targeted therapy is a new method and tendency in the treatment of hepatocellular carcinoma (HCC). To date, sorafinib, a multi-targeted gent, is the only one proved to be effective in improving the survival of patients with advanced HCC. Sorafinib is also the first line systemic agent for advanced HCC. Other multi-targeted agents, such as sunitinib, are also proved to be effective. Erlotinib, gefitinib and eetuximab, which target epidermal growth factor receptor, show effectiveness but still need further investigation. Bevacizumab, which targets vascular endothelial growth factor and vascular endothelial growth factor receptor, shows excellent results and deserves more clinical trials. The effects of bortezomib, sirolimus and imatinib, which target other pathways, are still under investigation. The future studies of molecular-targeted therapy for HCC should be focused on the combination of different targeted medicine, and combination of molecular-targeted therapy and chemotherapy, as well as individualized therapy. 相似文献
996.
Pretransplantation Donor–Recipient Pair Seroreactivity Against BK Polyomavirus Predicts Viremia and Nephropathy After Kidney Transplantation
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
H. F. Wunderink E. van der Meijden C. S. van der Blij‐de Brouwer M. J. K. Mallat G. W. Haasnoot E. W. van Zwet E. C. J. Claas J. W. de Fijter A. C. M. Kroes F. Arnold A. Touzé F. H. J. Claas M. C. W. Feltkamp 《American journal of transplantation》2017,17(1):161-172
Kidney transplant donors are not currently implicated in predicting BK polyomavirus (BKPyV) infection in kidney transplant recipients. It has been postulated, however, that BKPyV infection originates from the kidney allograft. Because BKPyV seroreactivity correlates with BKPyV replication and thus might mirror the infectious load, we investigated whether BKPyV seroreactivity of the donor predicts viremia and BKPyV‐associated nephropathy (BKPyVAN) in the recipient. In a retrospective cohort of 407 living kidney donor–recipient pairs, pretransplantation donor and recipient sera were tested for BKPyV IgG levels and correlated with the occurrence of recipient BKPyV viremia and BKPyVAN within 1 year after transplantation. Donor BKPyV IgG level was strongly associated with BKPyV viremia and BKPyVAN (p < 0.001), whereas recipient BKPyV seroreactivity showed a nonsignificant inverse trend. Pairing of high–BKPyV‐seroreactive donors with low‐seroreactive recipients resulted in a 10‐fold increased risk of BKPyV viremia (hazard ratio 10.1, 95% CI 3.5–29.0, p < 0.001). In multivariate analysis, donor BKPyV seroreactivity was the strongest pretransplantation factor associated with viremia (p < 0.001) and BKPyVAN (p = 0.007). The proportional relationship between donor BKPyV seroreactivity and recipient infection suggests that donor BKPyV seroreactivity reflects the infectious load of the kidney allograft and calls for the use of pretransplantation BKPyV serological testing of (potential) donors and recipients. 相似文献
997.
胆道术中胆汁细菌培养及药敏试验 总被引:1,自引:0,他引:1
目的 探讨胆道外科感染的常见病原微生物及其对 1 4种抗生素的敏感情况 ,为临床用药提供参考。方法 对近 3年来胆道手术中获取的胆汁标本进行培养和药敏实验。结果 32 5例胆汁标本培养以革兰氏阴性菌为主 (占 84 .3% ) ,其中大肠艾希氏菌 4 7例 (占 2 0 .4 % ) ,肠杆菌属 38例(占 1 6 .5 % )最多见。对革兰氏阴性菌较为敏感的有丁胺卡那霉素、万古霉素、环丙沙星。菌必治和复达欣对革兰氏阳性、阴性菌均敏感。结论 胆道外科感染主要选用针对革兰氏阴性杆菌和厌氧菌的抗生素 ,严重感染时须用广谱抗生素 ,结合外科引流原则 相似文献
998.
Nefyn H. Williams Ruth Lewis Nafees Ud Din Hosam E. Matar Deborah Fitzsimmons Ceri J. Phillips Alex Sutton Kim Burton Maggie Hendry Sadia Nafees Clare Wilkinson 《European spine journal》2013,22(9):1921-1935
Purpose
Systematic review comparing biological agents, targeting tumour necrosis factor α, for sciatica with placebo and alternative interventions.Methods
We searched 21 electronic databases and bibliographies of included studies. We included randomised controlled trials (RCTs), non-RCTs and controlled observational studies of adults who had sciatica treated by biological agents compared with placebo or alternative interventions.Results
We pooled the results of six studies (five RCTs and one non-RCT) in meta-analyses. Compared with placebo biological agents had: better global effects in the short-term odds ratio (OR) 2.0 (95 % CI 0.7–6.0), medium-term OR 2.7 (95 % CI 1.0–7.1) and long-term OR 2.3 [95 % CI 0.5 to 9.7); improved leg pain intensity in the short-term weighted mean difference (WMD) −13.6 (95 % CI −26.8 to −0.4), medium-term WMD −7.0 (95 % CI −15.4 to 1.5), but not long-term WMD 0.2 (95 % CI −20.3 to 20.8); improved Oswestry Disability Index (ODI) in the short-term WMD −5.2 (95 % CI −14.1 to 3.7), medium-term WMD −8.2 (95 % CI −14.4 to −2.0), and long-term WMD −5.0 (95 % CI −11.8 to 1.8). There was heterogeneity in the leg pain intensity and ODI results and improvements were no longer statistically significant when studies were restricted to RCTs. There was a reduction in the need for discectomy, which was not statistically significant, and no difference in the number of adverse effects.Conclusions
There was insufficient evidence to recommend these agents when treating sciatica, but sufficient evidence to suggest that larger RCTs are needed.Electronic supplementary material
The online version of this article (doi:10.1007/s00586-013-2739-z) contains supplementary material, which is available to authorized users. 相似文献999.
D. Kumar V. H. Ferreira P. Campbell K. Hoschler A. Humar 《American journal of transplantation》2017,17(1):281-286
Influenza vaccine is known to have suboptimal immunogenicity in transplant recipients. Despite this, influenza vaccine may have the added benefit of inducing a cross‐reactive immune response to viral strains not found in the vaccine. This is termed “heterologous immunity” and has not been assessed previously in transplant patients. Pre‐ and postvaccination sera from kidney transplant recipients (n = 60) immunized with the 2012–2013 adjuvanted or nonadjuvanted influenza vaccine underwent testing by hemagglutination inhibition assay for strains not present in vaccine: A/New Caledonia/20/99 (H1N1), A/Texas/50/2012 (H3N2) and B/Brisbane/60/2008. The geometric mean titer of antibody to heterologous strains increased after vaccine (H1N1: 80.0 to 136.1, p < 0.001; H3N2: 23.3 to 77.3, p < 0.001; B: 13.3 to 19.5, p < 0.001). Seroconversion rates were 16.7%, 41.7%, and 13.3%, respectively. No differences in heterologous response were seen in the adjuvanted versus nonadjuvanted groups. Patients were more likely to seroconvert for a cross‐reactive antigen if they seroconverted for the specific vaccine antigen. Seroconversion to heterologous A/H3N2, for example, was 84.0% for homologous H3N2 seroconverters versus 11.4% for nonseroconverters (p < 0.001). This study provides novel evidence that transplant recipients are able to mount significant cross‐protective responses to influenza vaccine that may be an additional, previously unknown benefit of immunization. 相似文献
1000.
Nosocomial BK Polyomavirus Infection Causing Hemorrhagic Cystitis Among Patients With Hematological Malignancies After Hematopoietic Stem Cell Transplantation
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Kato T. Mori T. Suzuki M. Ito T. C. Li M. Sakurai Y. Yamane R. Yamazaki Y. Koda T. Toyama N. Hasegawa S. Okamoto 《American journal of transplantation》2017,17(9):2428-2433
BK polyomavirus (BKPyV) is recognized as a pathogen that causes diseases such as hemorrhagic cystitis and nephritis after allogeneic hematopoietic stem cell transplantation (HSCT) or renal transplantation. BKPyV‐associated disease is thought to occur through reactivation under immunosuppression. However, the possibility of its nosocomial transmission and the clinical significance of such transmission have not been elucidated. During a 6‐month period, nine adult patients (median age: 47 years) who had hematological disorders and who were treated with HSCT (n = 7) or chemotherapy (n = 2) in a single hematology department developed hemorrhagic cystitis due to BKPyV infection. The polymerase chain reaction products of BKPyV DNA obtained from each patient were sequenced. Of the nine patients, six had subtype I, 2 had subtype IV, and 1 had subtype II or III. In the alignment of sequences, four and two of the six subtype I strains were completely homologous (100%). These results strongly suggest that BKPyV has the potential to cause nosocomial infection within a medical facility, especially among recipients of HSCT. Further studies are clearly warranted to elucidate the route(s) of BKPyV transmission in order to establish optimal infection control. 相似文献